<DOC>
	<DOCNO>NCT00655512</DOCNO>
	<brief_summary>compare atrophogenic potential pimecrolimus 1 % cream , hydrocortisonacetat 1 % cream , betamethasonvalerat 0,1 % cream clobetasol-17-Propionat 0,05 % cream</brief_summary>
	<brief_title>Comparison Skin Thickness Under Treatment With Pimecrolimus 1 % Cream , Hydrocortisonacetat 1 % Cream , Betamethasonvalerat 0,1 % Cream Clobetasol-17-propionat 0,05 % Cream Assessed Optical Coherence Tomography ( OCT ) 20-MHZ Ultrasound</brief_title>
	<detailed_description />
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>male female probands age 1840 year skin healthy skintype IIII accord Fitzpatrick woman childbearing potential without adequate contraception pregnant breastfeeding genetic defect epidermal barrier external systemic treatment drug , probably effect thickness skin production teleangiektasien within last 6 month study entry skin disease , hind evaluation OCT , ultrasound dermaphot UV treatment within last 4 week study entry participation another clinical trial within last 30 day study entry allergy pimecrolimus hydrocortison betamethasonvalerat Clobetasol17propionat severe systemic disease ; ongoing immunosuppressive treatment plan vaccination realize study entry 28 day end treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>pimecrolimus</keyword>
	<keyword>hydrocortison</keyword>
	<keyword>betamethasone</keyword>
	<keyword>clobetasol-17-Propionat</keyword>
	<keyword>Optical Coherence Tomography</keyword>
	<keyword>skin healthy probands</keyword>
</DOC>